0

Rare Hemophilia Factors Market by Method and Geography - Forecast and Analysis 2022-2026

  • Published: Jun 2022
  • Pages: 98
  • SKU: IRTNTR72618
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The rare hemophilia factors market share is expected to increase to USD 146.76 million from 2021 to 2026, at a CAGR of 7.4%.

This rare hemophilia factors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers rare hemophilia factors market segmentation by method (fresh frozen plasma, factor concentrates, cryoprecipitate, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The rare hemophilia factors market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, and Intermountain Healthcare among others.

What will the Rare Hemophilia Factors Market Size be During the Forecast Period?

Rare Hemophilia Factors Market Size

Download the Free Report Sample to Unlock the Rare Hemophilia Factors Market Size for the Forecast Period and Other Important Statistics

 

Rare Hemophilia Factors Market: Key Drivers, Trends, and Challenges

The approval of new treatment techniques is notably driving the rare hemophilia factors market growth, although factors such as cost-intensive and complex treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the rare hemophilia factors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Rare Hemophilia Factors Market Driver

One of the key factors driving the global rare hemophilia factors market growth is the approval of new treatment techniques. Patients with hemophilia have the option of choosing different effective and safe treatments, including novel extended half-life therapeutics that can overcome the current prophylaxis limitations, particularly in patients with hemophilia B. Among the different types of hemophilia, A and B are the most common. According to the CDC, every year, hemophilia A affects 1 in 5,000 male births, and approximately 400 babies are born with hemophilia A each year in the US. Therapies such as replacement therapy for hemophilia A and hemophilia B provide missing coagulation factors and have been the mainstay of treatment in hemophilic patients. Several players in the market are focused on identifying novel strategies to treat hemophilia. For instance, in February 2020, Novo Nordisk launched the US FDA-approved ESPEROCT to treat adults and children with hemophilia A. Such factors will drive market growth in the coming years. 

Key Rare Hemophilia Factors Market Trend

Advent of gene therapy is one of the key rare hemophilia factors market trends that is expected to impact the industry positively in the forecast period. The aim of gene therapy for hemophilia is to deliver stable insertion and expression of a gene, the absence of which is responsible for hemophilia A or B. Some examples of gene therapy development to treat hemophilia are listed below:

  • In December 2021, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, investigational gene therapy for patients with moderately severe to severe hemophilia A.
  • In May 2019, the company announced the submission of data from its Phase III clinical trial to regulators for approval. 

Key Rare Hemophilia Factors Market Challenge

One of the key challenges to the global rare hemophilia factors market growth is the cost-intensive and complex treatment. The current treatments pose certain limitations, such as the risk of infection, treatment resistance, poor compliance, and adverse effects. Recombinant therapies are associated with the development of inhibitors. It is estimated that approximately 30% of hemophilia A afflicted population undergoing therapy are susceptible to adverse immunogenic reactions. Plasma-based therapies are associated with the risk of transmission of blood-borne disorders such as HIV, hepatitis B, and hepatitis C. Though primary screening of blood is done, the risk of transmission of these infections during transfusion is high, due to the presence of different strains of pathogens. Such factors may impede market growth in the coming years.

This rare hemophilia factors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global rare hemophilia factors market as a part of the pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the rare hemophilia factors market during the forecast period.

Who are the Major Rare Hemophilia Factors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Alnylam Pharmaceuticals Inc.
  • Aptevo Therapeutics Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Catalyst Biosciences, Inc.
  • CSL Ltd.
  • F. Hoffmann La Roche Ltd.
  • Genentech Inc.
  • Grifols SA
  • Kedrion Spa
  • Novo Nordisk
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • The Johns Hopkins Health System Corp.
  • UCSF Health
  • uniQure NV
  • Versiti
  • Intermountain Healthcare

 

This statistical study of the rare hemophilia factors market encompasses successful business strategies deployed by the key vendors. The rare hemophilia factors market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

  • Bayer AG - The company offers rare hemophilia factors that provide substitution therapy which helps to protect you from joint bleeds and blood-borne viruses.
  • Aptevo Therapeutics Inc. - The company offers rare hemophilia factors that include adapters technology, adaptir-flex technology that helps to protect from joint bleeds, and blood-borne viruses.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The rare hemophilia factors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Rare Hemophilia Factors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the rare hemophilia factors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Rare Hemophilia Factors Market?

Rare Hemophilia Factors Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for rare hemophilia factors in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The presence of key market players and a significant increase in investment in R&D will facilitate the rare hemophilia factors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Method Segments in the Rare Hemophilia Factors Market?

Rare Hemophilia Factors Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The rare hemophilia factors market share growth by the fresh frozen plasma segment will be significant during the forecast period. Fresh frozen plasma is used to treat bleeding associated with an increased PT (>1.5 times normal) or aPTT (>2 times normal). In an average-sized adult, one unit of fresh frozen plasma increases coagulation factors by around 3%. For coagulopathic bleeding, a dose of 10 to 15 ml/kg (typically about four units) is sufficient for initial treatment. FFP is used in the treatment of many severe to chronic illnesses, which will drive the segment growth in the coming years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the rare hemophilia factors market size and actionable market insights on post COVID-19 impact on each segment.

 

Rare Hemophilia Factors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Decelerate at a CAGR of 7.4%

Market growth 2022-2026

$ 146.76 million

Market structure

Fragmented

YoY growth (%)

9.97

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key consumer countries

US, Canada, Germany, UK, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, and Intermountain Healthcare

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Rare Hemophilia Factors Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive rare hemophilia factors market growth during the next five years
  • Precise estimation of the rare hemophilia factors market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the rare hemophilia factors industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of rare hemophilia factors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market Segmentation by Method
    • Exhibit 05: Executive Summary – Data Table on Incremental Growth
    • Exhibit 06: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 07: Parent market
    • Exhibit 08: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 09: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 10: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 11: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 12: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 13: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 14: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 15: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 16: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 17: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 18: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 19: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 20: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 21: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Method

    • 5.1 Market segments
      • Exhibit 22: Chart on Method - Market share 2021-2026 (%)
      • Exhibit 23: Data Table on Method - Market share 2021-2026 (%)
    • 5.2 Comparison by Method
      • Exhibit 24: Chart on Comparison by Method
      • Exhibit 25: Data Table on Comparison by Method
    • 5.3 Fresh frozen plasma - Market size and forecast 2021-2026
      • Exhibit 26: Chart on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million)
      • Exhibit 27: Data Table on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million)
      • Exhibit 28: Chart on Fresh frozen plasma - Year-over-year growth 2021-2026 (%)
      • Exhibit 29: Data Table on Fresh frozen plasma - Year-over-year growth 2021-2026 (%)
    • 5.4 Factor concentrates - Market size and forecast 2021-2026
      • Exhibit 30: Chart on Factor concentrates - Market size and forecast 2021-2026 ($ million)
      • Exhibit 31: Data Table on Factor concentrates - Market size and forecast 2021-2026 ($ million)
      • Exhibit 32: Chart on Factor concentrates - Year-over-year growth 2021-2026 (%)
      • Exhibit 33: Data Table on Factor concentrates - Year-over-year growth 2021-2026 (%)
    • 5.5 Cryoprecipitate - Market size and forecast 2021-2026
      • Exhibit 34: Chart on Cryoprecipitate - Market size and forecast 2021-2026 ($ million)
      • Exhibit 35: Data Table on Cryoprecipitate - Market size and forecast 2021-2026 ($ million)
      • Exhibit 36: Chart on Cryoprecipitate - Year-over-year growth 2021-2026 (%)
      • Exhibit 37: Data Table on Cryoprecipitate - Year-over-year growth 2021-2026 (%)
    • 5.6 Others - Market size and forecast 2021-2026
      • Exhibit 38: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 39: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 40: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 41: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 5.7 Market opportunity by Method
      • Exhibit 42: Market opportunity by Method ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Drivers, Challenges, and Trends

    • 7.1 Market drivers
      • 7.2 Market challenges
        • 7.3 Impact of drivers and challenges
          • Exhibit 44: Impact of drivers and challenges in 2021 and 2026
        • 7.4 Market trends

          8 Vendor Landscape

          • 8.1 Overview
            • 8.2 Vendor landscape
              • Exhibit 45: Overview on Criticality of inputs and Factors of differentiation
            • 8.3 Landscape disruption
              • Exhibit 46: Overview on factors of disruption
            • 8.4 Industry risks
              • Exhibit 47: Impact of key risks on business

            9 Vendor Analysis

            • 9.1 Vendors covered
              • Exhibit 48: Vendors covered
            • 9.2 Market positioning of vendors
              • Exhibit 49: Matrix on vendor position and classification
            • 9.3 Aptevo Therapeutics Inc.
              • Exhibit 50: Aptevo Therapeutics Inc. - Overview
              • Exhibit 51: Aptevo Therapeutics Inc. - Product / Service
              • Exhibit 52: Aptevo Therapeutics Inc. - Key offerings
            • 9.4 Bayer AG
              • Exhibit 53: Bayer AG - Overview
              • Exhibit 54: Bayer AG - Business segments
              • Exhibit 55: Bayer AG - Key news
              • Exhibit 56: Bayer AG - Key offerings
              • Exhibit 57: Bayer AG - Segment focus
            • 9.5 CSL Ltd.
              • Exhibit 58: CSL Ltd. - Overview
              • Exhibit 59: CSL Ltd. - Business segments
              • Exhibit 60: CSL Ltd. - Key offerings
              • Exhibit 61: CSL Ltd. - Segment focus
            • 9.6 F. Hoffmann La Roche Ltd.
              • Exhibit 62: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 64: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 65: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 66: F. Hoffmann La Roche Ltd. - Segment focus
            • 9.7 Grifols SA
              • Exhibit 67: Grifols SA - Overview
              • Exhibit 68: Grifols SA - Business segments
              • Exhibit 69: Grifols SA - Key offerings
              • Exhibit 70: Grifols SA - Segment focus
            • 9.8 Novo Nordisk
              • Exhibit 71: Novo Nordisk - Overview
              • Exhibit 72: Novo Nordisk - Business segments
              • Exhibit 73: Novo Nordisk - Key offerings
              • Exhibit 74: Novo Nordisk - Segment focus
            • 9.9 Octapharma AG
              • Exhibit 75: Octapharma AG - Overview
              • Exhibit 76: Octapharma AG - Product / Service
              • Exhibit 77: Octapharma AG - Key offerings
            • 9.10 Pfizer Inc.
              • Exhibit 78: Pfizer Inc. - Overview
              • Exhibit 79: Pfizer Inc. - Product / Service
              • Exhibit 80: Pfizer Inc. - Key news
              • Exhibit 81: Pfizer Inc. - Key offerings
            • 9.11 Sanofi
              • Exhibit 82: Sanofi - Overview
              • Exhibit 83: Sanofi - Business segments
              • Exhibit 84: Sanofi - Key news
              • Exhibit 85: Sanofi - Key offerings
              • Exhibit 86: Sanofi - Segment focus
            • 9.12 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 90: Takeda Pharmaceutical Co. Ltd. - Key offerings

            10 Appendix

            • 10.1 Scope of the report
              • 10.2 Inclusions and exclusions checklist
                • Exhibit 91: Inclusions checklist
                • Exhibit 92: Exclusions checklist
              • 10.3 Currency conversion rates for US$
                • Exhibit 93: Currency conversion rates for US$
              • 10.4 Research methodology
                • Exhibit 94: Research methodology
                • Exhibit 95: Validation techniques employed for market sizing
                • Exhibit 96: Information sources
              • 10.5 List of abbreviations
                • Exhibit 97: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Rare Hemophilia Factors Market market growth will increase by $146.76 million during 2022-2026.
              The rare hemophilia factors market market is expected to grow at a CAGR of 7.4% during 2022-2026.
              Technavio has segmented the rare hemophilia factors market market by other 1 (Fresh frozen plasma, Factor concentrates, Cryoprecipitate, and Others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
              Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, Intermountain Healthcare are a few of the key vendors in the rare hemophilia factors market market.
              North America will register the highest growth rate of 41% among the other regions. Therefore, the rare hemophilia factors market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the rare hemophilia factors market market growth are:
              • Approval of new treatment techniques
              • Advent of gene therapy
              The rare hemophilia factors market market vendors should focus on grabbing business opportunities from the fresh frozen plasma segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>